New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 30, 2024 - Formycon and Fresenius Kabi announced the FDA approval of Otulfi (ustekinumab-aauz), biosimilar to Janssen’s Stelara® (ustekinumab).
Download PDF
Return to publications
